Highbury Group

Dr. Ling Wong is Founder and General Partner of Highbury Group and Sea Lane Ventures. She also serves as Senior Advisor to Lightspeed Venture Partners. Highbury Group was founded on the principle to be a true partner and champion to entrepreneurs, using science and technology to build companies that fundamentally transform the world for the betterment of humanity today, and in the future. Prior to Highbury, she served at the Gates Foundation where she helped to establish a $1.5B global investment portfolio and created a $200M early stage program to support early stage entrepreneurs in more than 60 countries. As a health and technology investor, Dr. Wong has been involved in some of the market’s most significant investments and exits. She has partnered with over fifteen $1B+ companies, including: Devoted Health, Orca Bio, Collective Health, Color, Apeel, Shape, Stripe, Offer Up, Rappi, Branch Metrics, Notion, Modern Animal, Wheel and Satellite Bio. Notable exits include: Anacor Pharmaceuticals (acquired by Pfizer for $5.2B), Genocea Biosciences (NASDAQ: GNCA), Visterra (acquired for $430M), Slack (NYSE: WORK), Guardant Health (NASDAQ: GH), and recently Singular Genomics (NASDAQ: OMIC). Dr. Wong holds a PhD from Harvard in Engineering Sciences, a BSc in Chemical Engineering and BSc in Biology from MIT. During her time at Harvard, she created the world’s first inhaled TB vaccine. Her scientific training has shaped how she assesses financial opportunities, both to create value and to benefit human health. Dr. Wong has always been passionate about seeking entrepreneurs and partners that are looking to disrupt the status quo in science and technology for the betterment of society.